A group from Jan Kochanowski University, Kielce, Poland, etc. has reported effectiveness of Tocilizumab and Dexamethasone in COVID-19 severe patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291861/
Comparing four groups (treated with Tocilizmab (TCZ), treated with TCZ and Dexamethason (DEX), treated with DEX, and no TCZ nor DEX), the death rate of 6.8% was significantly lower in patients receiving TCZ alone than other groups (19.6%–23.1%), particularly in patients with IL-6 concentration exceeding 100pg/mL, the death rate was significantly lower in patients receiving TCZ alone than other groups (5% vs 22.9%–51.7%, respectively).
The clinical improvements on day21 and day28 were also doubled in the case of TCZ alone (60% and 75%, respectively)comparing with that in that case of DEX alone (27.6% and 37.9%, respectively).
So, in patients with severe course of COVID-19, particularly those developing cytokine storm, administration of TCZ provides a significantly better effect than DEX regarding survival, clinical improvement, and hospital discharge rate. The combination of TCZ and DEX does not improve therapy effectiveness in patients with severe COVID-19 compared to the administration of TCZ alone.